# Advisor Review - GPT-5-mini

**Role:** Academic advisor checking for fatal errors
**Model:** openai/gpt-5-mini
**Paper:** paper.pdf
**Timestamp:** 2026-02-04T03:41:06.279283
**Route:** OpenRouter + LaTeX
**Tokens:** 20347 in / 1743 out
**Response SHA256:** 5a786dba3a6d7699

---

I checked the draft for fatal errors in the four required categories (Data-Design Alignment; Regression Sanity; Completeness; Internal Consistency), focusing only on the specified types of mistakes that would make the submission embarrassingly wrong or impossible to estimate. I inspected the main text, all tables/figures that are directly shown in the LaTeX source, and the appendices referenced in the text.

Summary judgment
- I found no fatal errors in any of the four categories. Everything required by your advisor checklist is present and internally consistent at the level visible in the manuscript source.

Notes on specific checks performed (brief)

1) Data-Design Alignment
- Treatment timing vs data coverage: The outcome data end in 2023 (NCHS 1999–2017 plus provisional 2020–2023 with a documented 2018–2019 gap). States with first-treatment years in 2024–2025 are explicitly reclassified as not-yet-treated for estimation; therefore max(treatment year) used in estimation ≤ max(data year) (2023). No impossible timing claims were made (the cohort table lists treated cohorts only through 2023). PASS.
- Post-treatment observations: The earliest treatment year is 2020; the paper documents up to four post-treatment years for earliest cohorts (2020→2020–2023 available), and it documents the 2018–2019 gap transparently. Vermont’s exclusion due to suppression is clearly described and sensitivity checks for Vermont are reported. The paper states explicitly which states/cohorts are actually observed post-treatment. PASS.
- Treatment definition consistency: Policy database construction and cohort assignment are described, and the cohort composition table matches the narrative (17 treated states observed in-sample, 8 reclassified as not-yet-treated, 25 never-treated, Vermont separately noted). The treatment coding convention (first full calendar year; mid-year effective dates assigned forward) is stated. No inconsistency detected. PASS.

2) Regression Sanity
- Checked reported coefficients and standard errors shown in the text and in reproduced small tables/figures:
  - TWFE baseline: coefficient −0.117, SE = 1.115 — plausible for a mortality rate outcome (per 100k).
  - Callaway–Sant’Anna: 0.922, SE = 0.744 — plausible.
  - Sun-Abraham: 1.052, SE = 0.786 — plausible.
  - COVID-sensitivity table SEs and CIs are on similar scales.
- No insanely large standard errors, no coefficient magnitudes >100, no R² out-of-range values reported, and no "NA"/"NaN"/"Inf" strings visible in the displayed results or narrative.
- The manuscript also documents cluster counts (clusters = 50) and total non-suppressed observations (N = 1,142) in figure/table captions. No regression-sanity red flags visible in the source. PASS.

3) Completeness
- I checked for placeholder tokens ("NA", "TBD", "TODO", "PLACEHOLDER", "XXX") in the main text and appendices: none found.
- The paper reports sample sizes and cluster counts in captions and in the sample construction section (1,142 state-year observations, clusters = 50). Regression tables in the text present standard errors and CIs; the manuscript also details the inference methods (multiplier bootstrap, CR2, wild cluster bootstrap). The description of suppressed cells and suppression sensitivity checks is present.
- All referenced tables/figures are present in the LaTeX source via \input or defined figures, and the text does not refer to missing figures/tables. The appendices include variable definitions, robustness appendix, and cohort table. I did not encounter empty table placeholders. PASS.

4) Internal Consistency
- Numbers cited in the text match the numbers shown in tables/captions (e.g., N = 1,142, clusters = 50; 17 treated states observed in-sample; 8 reclassified as not-yet-treated), and the narrative about the 2018–2019 gap, Vermont exclusion, and reclassification of late adopters is consistently applied throughout.
- Treatment timing is consistently described across sections and the cohort composition table aligns with the policy descriptions.
- Specification labels (TWFE, Callaway–Sant'Anna, Sun–Abraham) are used consistently, and controls (e.g., Medicaid expansion, COVID controls) are described and reported consistently across robustness checks.
- Minor textual differences (e.g., one place describes "up to 25 years (1999–2023)" while the sample-construction arithmetic uses 23 available years given the gap) are editorial/clarifying issues but not fatal or contradictory for identification. No internal contradictions affecting the estimand or feasibility were found. PASS.

Conclusion
- I found zero fatal errors (none in data-design alignment, regression sanity, completeness, or internal consistency that would block submission).

ADVISOR VERDICT: PASS